Skip to content

The Impact of Liposomal Bupivacaine Interscalene Plexus Block at Different Planes on the Quality of Postoperative Recovery in Patients Undergoing Arthroscopic Shoulder Surgery

The Impact of Liposomal Bupivacaine Interscalene Plexus Block at Different Planes on the Quality of Postoperative Recovery in Patients Undergoing Arthroscopic Shoulder Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095356
Enrollment
Unknown
Registered
2025-01-06
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Acute Pain

Interventions

Group A:Interscalene approach to supraclavicular brachial plexus block
10 mL (133 mg) liposomal bupivacaine + 5 mL normal saline
Group B:Traditional interscalene brachial plexus block
10 mL (133 mg) liposomal bupivacaine + 5 mL NS
Group C:Interscalene brachial plexus block
10 mL (50 mg) ropivacaine hydrochloride + 3 mg dexamethasone + 5 mL NS

Sponsors

Affiliated Hospital Of Jining Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. 18 years old<=age<=70 years old, male or female. 2. Patients undergoing shoulder arthroscopic surgery under elective general anesthesia consistent with nerve block. 3. American Society of Anesthesiologists (ASA) grade I-I?. 4. Understand the research process and the use of pain scales. 5. Subject has no contraindications to the study drug. 6. Have a clear understanding and voluntarily participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Prior neurological disease, cervical spine lesions (i.e., intervertebral disc herniation, myelopathy), chronic pain syndrome (defined as reflex sympathetic dystrophy or complex regional pain syndrome). 2. History of allergy to local anesthetic or study drug. 3. Severe respiratory disease, cardiovascular and cerebrovascular system disease, mental or cognitive impairment that causes the patient to be unable to comply with the study protocol. 4. History of drug or alcohol abuse, chronic opioid use (more than 3 months or more than 5 mg/day of morphine equivalent per day for 1 month). 5. Contraindications to general anesthesia and/or brachial plexus block. 6. Pregnancy. 7. Intraoperative decision to perform shoulder arthrotomy.

Design outcomes

Primary

MeasureTime frame
The area under the 72-hour resting pain NRS curve;Mean arterial pressure and heart rate;Amount of bleeding;Fluid replacement volume;Duration of the operation;Sufentanil consumption during the operation;The number of screws inserted into the shoulder joint;

Secondary

MeasureTime frame
Sleep time;Shoulder Function Score;Delirium Assessment;Incidence of adverse reactions related to nerve block;The time of numbness recession in the affected limb;Time of motor function recovery in the affected limb;Incidence of nausea and vomiting;Quality of Life Assessment;Postoperative sufentanil consumption;The area under the NRS curve of 72-hour exercise pain;

Countries

China

Contacts

Public ContactChengdong Zhang

Affiliated Hospital Of Jining Medical University

zcd812@163.com+86 186 7876 8798

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026